MedTrace Logo

Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

NCT05431634 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2023-05-09

No results posted yet for this study

Summary

Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants

Conditions

  • Safety and Tolerability

Interventions

DRUG

Experimental drug: ESK-001

Multiple doses of ESK-001

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Alumis Inc

    lead INDUSTRY

Principal Investigators

  • Mark Bradley · Alumis Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-12
Primary Completion
2022-12-01
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05431634 on ClinicalTrials.gov